IP Library Granted Patent US 12,678,460
Granted Patent B2
US 12,678,460 · App. 18/157,652 · Granted Jul 14, 2026

Methods for managing adverse events in patients with inflammation

Inventors: Andrew Dunham (Tower Lakes, IL); Tatsuro Yoshida (West Newton, MA); Samuel O. Sowemimo-Coker (Dix Hills, NY)
Assignee: Hemanext Inc.
A61K35/14A61P7/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,678,460
App. No.
18/157,652
Filed
Jan 20, 2023
Granted
Jul 14, 2026
Kind
B2
Art Unit
1655
USPC
424/529
Abstract

Methods for prevention and reversal of inflammation.

Claims (9)

1 . A method of improving a transfusion outcome in a sickle cell disease patient in need of a blood transfusion comprising administering stored oxygen reduced blood to the sickle cell disease patient, wherein the stored oxygen reduced blood comprises red blood cells having increased deformability, wherein the stored oxygen reduced blood has an oxygen saturation of 20% or less during a storage period, wherein the increased deformability is compared to conventionally stored blood stored for an identical storage period, and wherein the improved transfusion outcome comprises reduced occurrence of dactylitis, reduced occurrence of pain crises, reduced complications from anemia, reduced occurrence of infection, reduced spleen damage, reduced risk of stroke, or any combination thereof compared to a sickle cell disease patient having been administered conventionally stored blood stored for an identical storage period.

2 . The method of claim 1 , wherein the sickle cell disease is sickle cell anemia.

3 . The method of claim 1 , wherein the sickle cell disease is sickle cell crisis.

4 . The method of claim 1 , wherein the sickle cell disease is selected from the group consisting of hemoglobin SS (HbSS), hemoglobin SC (HbSC), hemoglobin S beta thalassemia+(HbSB+), hemoglobin S (beta-zero) thalassemia (HbSB), hemoglobin SD (HbSD), hemoglobin SE (HbSE), and hemoglobin SO (HbSO).

5 . The method of claim 1 , wherein the sickle cell disease patient experiences an improved recovery at 24 hours after the administration compared to a sickle cell disease patient having been administered conventionally stored blood stored for an identical time period, and wherein the improved recovery is maintenance of a normal hematocrit level.

6 . The method of claim 1 , wherein the increased deformability compared to conventionally stored blood is when the stored oxygen reduced blood is in the presence of sickle cell plasma.

7 . The method of claim 1 , further comprising reducing carbon dioxide in the stored oxygen reduced blood.

8 . The method of claim 1 , wherein the complications from anemia are selected from the group consisting of fatigue, irritability, dizziness, difficulty breathing, pale skin color, jaundice, slow growth, and delayed puberty.

9 . The method of claim 1 , wherein the spleen damage is splenic sequestration or splenic enlargement.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 23, 2023
From: DUNHAM, ANDREW; YOSHIDA, TATSURO; SOWEMIMO-COKER, SAMUEL O
To: NEW HEALTH SCIENCES, INC.
Reel/Frame 062456/0308 →
CHANGE OF NAME Recorded Jan 23, 2023
From: NEW HEALTH SCIENCES, INC.
To: HEMANEXT INC.
Reel/Frame 062463/0837 →
Continuity (3)
Continuation 17292597 · Nov 14, 2019
Provisional Application 62768667 · Nov 16, 2018
Related Publication 20230248767A1 · Aug 10, 2023
References Cited (70)
US 4769318A · Hamasaki et al. · 1988 [cited by applicant]
US 4880786A · Sasakawa et al. · 1989 [cited by applicant]
US 5476764A · Bitensky · 1995 [cited by applicant]
US 5624794A · Bitensky et al. · 1997 [cited by applicant]
US 5789151A · Bitensky et al. · 1998 [cited by applicant]
US 6162396A · Bitensky et al. · 2000 [cited by applicant]
US 6413713B1 · Serebrennikov · 2002 [cited by applicant]
US 6447987B1 · Hess et al. · 2002 [cited by applicant]
US 10603417B2 · Yoshida · 2020 [cited by examiner]
US 11013771B2 · Yoshida et al. · 2021 [cited by applicant]
US 11090331B2 · D'Alessandro et al. · 2021 [cited by applicant]
US 11433164B2 · Yoshida · 2022 [cited by examiner]
US 11576931B2 · Dunham et al. · 2023 [cited by applicant]
US 20120129149A1 · Federspiel · 2012 [cited by examiner]
US 20130004937A1 · Yoshida et al. · 2013 [cited by applicant]
US 20210401883A1 · Dunham et al. · 2021 [cited by applicant]
CN 103037869A · 2013 [cited by applicant]
CN 103732056A · 2014 [cited by applicant]
CN 107735095A · 2018 [cited by applicant]
WO WO2016187353A1 · 2016 [cited by applicant]
WO WO2017223377A1 · 2017 [cited by applicant]
WO WO2020102602 · 2020 [cited by applicant]
Brown et al., “Length of red cell unit storage and risk for delirium after cardiac surgery,” [cited by applicant]
Chaplin et al., “The proper use of previously frozen red blood cells for transfusion,” [cited by applicant]
Ciccia et al., “Pediatric acute kidney injury: prevalence, impact and management challenges,” [cited by applicant]
D'Alessandro et al., “An update on red blood cell storage lesions, as gleaned through biochemistry and omics technologies,” [cited by applicant]
D'Alessandro et al., “Citrate metabolism in red blood cells stored in additive solution-3,” [cited by applicant]
D'Alessandro et al., “Metabolomics of AS-5 RBC supernatants following routine storage,” [cited by applicant]
D'Alessandro et al., “Omics markers of the red cell storage lesion and metabolic linkage,” [cited by applicant]
D'Alessandro et al., “Red blood cell storage in additive solution-7 preserves energy and redox metabolism: a metabolomics approach,” [cited by applicant]
D'Alessandro et al., “Routine storage of red blood cell (RBC) units in additive solution-3: a comprehensive investigation of the RBC metabolome,” [cited by applicant]
Flegel et al., “Does prolonged storage of red blood cells cause harm?” [cited by applicant]
Fox et al., “Earlier Endpoints Are Required for Hemorrhagic Shock Trials among Severely Injured Patients,” [cited by applicant]
Gowda, et al., “Markers of renal function tests,” [cited by applicant]
Hashmi et al., “Predictors of mortality in geriatric trauma patients: A systematic review and meta-analysis,” [cited by applicant]
Hod et al., “Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron,” [cited by applicant]
International Search Report dated Jan. 31, 2020 in Int'l Appln. PCT/US2019/061565. [cited by applicant]
Jy et al., “Microparticles in stored red blood cells as potential mediators of transfusion complications,” [cited by applicant]
Kim-Shapiro et al., “Storage lesion: role of red blood cell breakdown,” [cited by applicant]
Kleiner., et al., “Cytokine Levels in the Serum of Healthy Subjects,” [cited by applicant]
Kreutziger et al., “Admission blood glucose predicted haemorrhagic shock in multiple trauma patients,” [cited by applicant]
Laird et al., “Relationship of Early Hyperglycemia to Mortality in Trauma Patients,” [cited by applicant]
Liu et al., “Mechanism of faster NO scavenging by older stored red blood cells,” [cited by applicant]
Norton, et al., “Injuries,” [cited by applicant]
Platt, “Sickle cell anemia as an inflammatory disease,” [cited by applicant]
Prestia et al., “Transfusion of stored blood impairs host defenses against Gram-negative pathogens in mice,” [cited by applicant]
Redlin et al., “Red Blood Cell Storage Duration Is Associated with Various Clinical Outcomes in Pediatric Cardiac Surgery,” [cited by applicant]
Régnier et al., “Prognostic Significance of Blood Lactate and Lactate Clearance in Trauma Patients,” [cited by applicant]
Reisz et al., “Oxidative modifications of glyceraldehyde 3-phosphate dehydrogenase regulate metabolic reprogramming of stored red blood cells e-blood,” Blood, 128(12):e32-e42 (2016). [cited by applicant]
Reynolds et al., “The transfusion problem: role of aberrant S-nitrosylation,” [cited by applicant]
Roback et al., “Insufficient nitric oxide bioavailability: a hypothesis to explain adverse effects of red blood cell transfusion,” [cited by applicant]
Roback et al., “Metabolomics of ADSOL (AS-1) Red Blood Cell Storage,” [cited by applicant]
Rogers et al., “Storage Duration of Red Blood Cell Transfusion and [cited by applicant]
Spinella et al., “Does the storage duration of blood products affect outcomes in critically ill patients?” [cited by applicant]
Spinella et al., “Properties of stored RBCs: Understanding immune and vascular reactivity,” [cited by applicant]
Treeprasertsuk et al., “Urine neutrophil gelatinase-associated lipocalin: a diagnostic and prognostic marker for acute kidney injury (AKI) in hospitalized cirrhotic patients with AKI-prone conditions,” [cited by applicant]
Valeri et al., “The survival, function, and hemolysis of human RBCs stored at 4°C in additive solution (AS-1, AS-3, or AS-5) for 42 days and then biochemically modified, frozen, thawed, washed, and stored at 4° in sodiu… [cited by applicant]
Wang et al., “Transfusion of older stored blood worsens outcomes in canines depending on the presence and severity of pneumonia,” [cited by applicant]
Weinberg et al., “Red blood cell age and potentiation of transfusion-related pathology in trauma patients,” [cited by applicant]
Wither et al., “Hemoglobin oxidation at functional amino acid residues during routine storage of red blood cells,” [cited by applicant]
Yoshida et al., “Extended storage of red blood cells under anaerobic conditions,” [cited by applicant]
Yoshida et al., “The effects of additive solution pH and metabolic rejuvenation on anaerobic storage of red cells,” [cited by applicant]
Yoshida et al. “Reduction of microparticle generation during anaerobic storage of red blood cells,” [cited by applicant]
Zhang et al., “Lactate clearance is a useful biomarker for the prediction of all- cause mortality in critically ill patients: a systematic review and meta-analysis,” [cited by applicant]
Zhu et al., “Impaired adenosine-5′ triphosphate release from red blood cells promotes their adhesion to endothelial cells: a mechanism of hypoxemia after transfusion,” [cited by applicant]
Zimring, “Established and theoretical factors to consider in assessing the red cell storage lesion,” [cited by applicant]
Search Report dated Dec. 4, 2023 issued in Chinese Appln. 201980079192.0. [cited by applicant]
He et al., “24. Effect of Active Oxygen on the Rheological Properties of Red Aluminum, Its Mechanism and Its Electrochemical Significance,” [cited by applicant]
Hu et al., “18. Pleural Effusion and ascites,” [cited by applicant]
[cited by applicant]